Relying on Guardant Reveal for continued health

The healthcare sector is experiencing a remarkable transformation driven by advancements in technology and an increasing focus on personalised medicine. Among the significant trends shaping the industry are the integration of artificial intelligence (AI) and machine

Cambridge-based EDX Medical is set to introduce a diagnostic tool in the UK aimed at identifying patients’ risk of developing hereditary cancer. This tool, which remains unnamed, focuses on germline testing. While mutations in tumours, particularly

Nucleic acid-based biomarkers are integral to precision medicine, acting as indicators for a range of biological states, from disease predisposition to therapeutic effectiveness. Their application in numerous diseases necessitates thorough studies to identify them, comprehend their

EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development

Guardant Health, Inc. (NASDAQ: GH), a precision oncology company, has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746) for its Guardant360® CDx blood test. This certification, granted by TÜV SÜD Product Service,

The Guardant360 CDx blood test has received certification from TÜV SÜD Product Service under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746) for tumour mutation profiling in patients with solid tumours. This certification also includes